The Group Research Institute integrates national, provincial, and municipal R&D platforms, and has been authorized as National Enterprise Technology Center, Guangdong Key Laboratory of Cardiovascular Drug R&D Enterprises, Guangdong Engineering Technology Research Center for Cardiovascular Drugs, Guangdong Provincial Academician Workstation, Shenzhen Engineering Laboratory for Cardiovascular Drug and Device Development, Postdoctoral Research Workstation, and Chengdu Engineering Technology Research Center for Novel Antibody Drugs. Our research involves multiple fields, including the research and development of gene therapy drugs, antibody drugs, recombinant protein drugs, small molecule innovative drugs, small nucleic acid and peptide drugs, as well as cardiovascular and cerebrovascular medical devices. These platforms provide strong technical support for innovative product R&D, ensuring the continuous driving of the company's rapid development in the future.
Chemical drugs
National-level Enterprise Technology Center
Recognized as the National Certified Enterprise Technology Center in 2012. ①;
Established a management system featuring multiple innovative models, such as independent R&D and integration of industry, academia and research. Built a proprietary technology development system with independent intellectual property rights.
Constantly optimize the product structure to accelerate the transformation of technological achievements into productivity.
Established the Innovative Drug Discovery Center, Drug R&D Center, and Joint Laboratories in accordance with the characteristics of drug research and development in different categories.
Established joint research centers with institutions such as the Shanghai Institute of Pharmaceutical Industry, Tsinghua University, and Sichuan University to provide follow-up support for product reserve and technology upgrading.
Postdoctoral Research Workstat
Recognized as postdoctoral innovation practice base In 2013, and obtained qualification as enterprise postdoctoral workstation in 2015.
The workstation mainly gathers top-tier talent teams to enhance the independent innovation capacity of the enterprise.
The postdoctoral research projects strengthened the construction of high-level professional and technical talent teams in enterprises, and promote the implementation of talent strategies and innovation-driven development strategies of enterprise.
The company has set up a scientific research and innovation team for postdoctoral researchers within the workstation, supported by skilled experts and professors from domestic prestigious universities as their co-cooperation instructors, and equipped with research assistants to ensure the maximum research contribution of postdoctoral researchers.
Provincial Key Laboratory of Enterprise
Established screening platform for the discovery of small molecule innovative drugs.
Established R&D platforms for siRNA small nucleic acid and gene editing drugs.
Established multiple in vivo pharmacodynamic and disease models.
Established R&D platform for oral cyclic peptides and long-acting cyclic peptides drugs.
Established a comprehensive in vivo/ in vitro pharmacokinetic evaluation system to support the early-stage screening of innovative drugs, the identification and optimization of lead compounds, and conduct in-depth assessment of the pharmacokinetic characteristics such as absorption, distribution, and metabolism of candidate compounds.
Provincial Engineering Technology Research Center
Established engineering technology platform for chemical raw materials.
Overcame key technical challenges in chemical raw material industrialization.
Provide chemical raw materials with high-quality, cost-effectiveness and environmental friendship, enhance the clinical value of chemical drug formulations.
Biologics
As the R&D and manufacturing platform of Salubris’ macromolecular drugs, the biologics sector serves the strategic objectives of Salubris. Focusing on cardiovascular, metabolism, orthopedics, oncology and other fields, the biologics sector provides biopharmaceutical pipelines for Salubris.
The biologics sector includes SalubrisBio (USA), Salubris (Chengdu) Biotech Co. , Ltd. and Salubris (Suzhou) Pharmaceuticals Co., Ltd.
Innovative Macromolecule R&D Center
SalubrisBio (USA) is dedicated to the development of novel therapeutic molecules and the discovery and development of innovative complex biologics for the treatment of cancer and cardiovascular diseases, as well as the development of novel and complex biologic therapies.
SalubrisBio focuses on complex biological agents, including combining bioactive proteins, activating the immune system against cancer-specific targets, and delivering anti-cancer drugs directly and specifically to tumors.
Macromolecule R&D Center
Salubris Chengdu is dedicated to the research and development of innovative biopharmaceuticals, focusing on the fields of cardiovascular and cerebrovascular diseases, oncology, metabolism, and osteoporosis. It has established three innovative drug R&D platforms for recombinant protein drugs, antibody drugs, and ADC drugs, and possesses a complete chain of innovative drug development from molecular design, cell line construction, process development, quality research, clinical studies to industrialization.
Salubris Chengdu has received support from the National Major New Drug Innovation Program's technical platform during the 12th Five-Year Plan, and the new drug projects of the Major New Drug Innovation Program during the 13th Five-Year Plan.
Established a distinctive pipeline for osteoporosis, forming a competitive advantage in osteoporosis therapeutic field in China. Meanwhile, products in the fields of heart failure, oncology, nephrology, weight loss, and lipid-lowering have been laid-out and are at different stages of development.
Macromolecular Drug Production Center
Salubris Suzhou has established E. coli fermentation workshops, mammalian cell culture workshops, protein purification system, lyophilized preparation workshops, cartridge vial filling lines, pre-filled syringe filling lines and QC laboratories etc. Currently, osteoporosis drugs Xinfutai® and Xinfutai Pro® are in production and sales. Both have successfully passed the combined inspection and the annual post-marketing product inspection, and have received high praise.
In addition to continuing the development of antibodies and ADCs in the fields of recombinant proteins and peptides, the biopharmaceutical sector will seek breakthroughs in gene therapy, cell therapy, and RNA interference.
Medical devices
Focusing on the demands of comprehensive prevention and treatment of cardiovascular diseases, carry out supporting research and development on cardiovascular prevention and therapeutic drugs, as well as interventional medical devices, to form a systematic and scientific prevention and treatment system.
Salubris Medicine Science and Technology Park
Develop a distinctive comprehensive development platform combining cardiovascular prevention and treatment drugs with interventional medical devices.
Note:
① Issuing institution: National Development and Reform Commission/Ministry of Science and Technology of the People's Republic of China/Ministry of Finance of the People's Republic of China/General Administration of Customs.P.R.China/State Taxation Administration.
